University of Ioannina
Πλειοτροπικές δράσεις αγωνιστών αιμοπεταλιακών υποδοχέων: υποκείμενοι μηχανισμοί και παθοφυσιολογικός ρόλος
Abstract
dc:descriptionTicagrelor, a potent platelet P2Y12 receptor (P2Y12R), is unique among antiplatelet drugs because it inhibits the P2Y12R in a reversible manner as well as it demonstrates a variety of advantageous pleiotropic effects associated probably with the increased concentration of adenosine. The pleiotropic effects of ticagrelor include cardioprotection, myocardium restoration after an ischemic event, and promotion of anticoagulative factor release as well as anti-inflammatory effects. However, beyond these advantageous effects, the increased adenosine concentration is also responsible for some adverse effects of ticagrelor including dyspnea and bradycardia. Aim of the present study was to shed more light into the mechanisms underlying the pleiotropic effects of ticagrelor. We investigated whether ticagrelor, either directly through P2Y12R or indirectly through adenosine, has the ability to affect the platelet-induced the CD34+ progenitor cell differentiation into endothelial progenitor cells (EPCs) as well as the functionality of EPCs and mature endothelial cells. These data will be important components of the mechanisms which are involved in the pathophysiology of cardiovascular disease. Materials and Methods: The effect of ticagrelor, as well as the role of adenosine, was studied on the expression of the endothelial phenotype (membrane expression of KDR) by CD34+ progenitor cells as well as on the interaction of platelets with CD34+ and CD34+/KDR+ cells followed by ADP- and TRAP-6-activation using flow cytometry. We also studied the effect of platelet suspension and supernatant on the functionality of EPCs. In particular, the effect of platelet suspension was studied on the membrane expression of the adhesion molecule ICAM-1 using flow cytometry as well as on the secretion of prostacyclin (PGI2) and monocyte chemoattractant protein-1 (MCP-1) using ELISA from late-outgrowth endothelial cells (OECs). The effect of platelet supernatant was also studied on the above described endothelial cell markers. Furthermore, we evaluated the effect of both ticagrelor and adenosine on the ability of EPCs to integrate into vascular structures forming capillary-like tubes and sprouts from cell spheroids. All experiments were also conducted in human umbilical vein endothelial cells (HUVECs). Results: Ticagrelor increased the ADP- and TRAP-6-induced membrane expression of KDR on CD34+ progenitor cells, which was further amplified in the presence of the combination of ticagrelor with adenosine, an effect which was inhibited by the inverse agonist and antagonist of the A2B adenosine receptor (AR), MRS1706. Ticagrelor reduced the ADP-induced interaction of platelets with CD34+ cells in contrast to the TRAP-6-induced intercellular interaction which was not affected by ticagrelor. Ticagrelor also increased the ADP- and TRAP-6-induced interaction of platelets with CD34+/KDR+ cells, which was further amplified in the presence of adenosine. Ticagrelor increased the membrane expression of ICAM-1 in the presence of activated platelets on OECs, an effect which was also observed in the presence of resting platelets but not in the presence of ADP-activated platelets. Similar results were also observed for the secretion of PGI2 and MCP-1 from OECs. Finally, both ticagrelor and adenosine increased the capillary-like tube formation as well as the sprout formation on cell spheroids formed by OECs. Sprout formation was inhibited either in the presence of the A2AAR antagonist, SCH58621, or in the presence of the A2BAR inverse agonist and antagonist, MRS1706, while their combination inhibited totally the above described phenomenon. Similar results were also observed when HUVECs were used. Conclusion: The present study demonstrates that ticagrelor induces the differentiation of CD34+ progenitor cells into EPCs as well as their ability to integrate into vascular structures, phenomena which are probably mediated through adenosine contributing thus to endothelial regeneration and neoangiogenesis. Furthermore, the present study demonstrates that resting and not activated platelets induce the activation of EPCs. This phenomenon is also observed in the presence, even after platelet activation, suggesting that ticagrelor may promote endothelial regeneration by inhibiting platelet activation and thus allowing resting platelets to activate EPCs.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Sidiropoulou, Sofia
- Σιδηροπούλου, Σοφία
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46966